In this episode of Phase Forward, Dr. Ana Palijan explores how early phase clinical trials have evolved beyond their traditional safety focus. With over 25 years in translational research, she discusses the growing complexity driven by scientific advances, technology integration, and global trial execution. Dr. Palijan highlights the shift toward context-specific strategies, the double-edged role of digital systems, and the rising value of niche CROs. She also examines the operational challenges faced by small biotech companies and the importance of aligning trial design with study intent. Tune in for a deep dive into the future of early clinical development.